{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:41:51Z","timestamp":1791906111925,"version":"4.3.4"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug-induced immune hemolytic anemia (DIIHA) is rare, and a specialized laboratory is often required to provide the optimal serological tests to confirm the diagnosis. The most common drugs associated with DIIHA and the hypotheses for the mechanisms thought to be involved have changed during the last few decades. The drugs most frequently associated with DIIHA at this time are cefotetan, ceftriaxone, and piperacillin. DIIHA is attributed most commonly to drug-dependent antibodies that can only be detected in the presence of drug (eg, cephalosporin antibodies). DIIHA can also be associated with drug-independent antibodies; such antibodies do not need drug to be present to obtain in vitro reactions (eg, fludarabine). In these latter cases, the drug affects the immune system, causing production of red cell (RBC) autoantibodies; the clinical and laboratory findings are identical to autoimmune hemolytic anemia (AIHA), other than the remission associated with discontinuing the drug. Some of the mechanisms involved in DIIHA are controversial. The most acceptable one involves drugs, like penicillin, that covalently bind to proteins (eg, RBC membrane proteins); RBCs become coated with drug in vivo and, a drug antibody (usually IgG) attaches to the drug-coated RBCs that are subsequently cleared by macrophages. The most controversial is the so-called immune complex mechanism, which has been revised to suggest that most drugs are capable of binding to RBC membrane proteins, but not covalently like penicillins. The combined membrane plus drug can create an immunogen; the antibodies formed can be IgM or IgG and often activate complement, leading to acute intravascular lysis and sometimes renal failure; fatalities are more common in this group. It is still unknown why and how some drugs induce RBC autoantibodies, sometimes causing AIHA.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.73","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":196,"title":["Drug-induced immune hemolytic anemia"],"prefix":"10.1182","volume":"2009","author":[{"given":"George","family":"Garratty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702203906000_R1","doi-asserted-by":"crossref","unstructured":"Kaufman DW, Kelley JP, Johannes CB, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993;82:2714\u20132718.","DOI":"10.1182\/blood.V82.9.2714.2714"},{"key":"2019111702203906000_R2","doi-asserted-by":"crossref","unstructured":"van den Bemt PMLA, Meyboom RHB, Egberts ACG. Drug-induced immune thrombocytopenia. Drug Safety. 2004;27:1243\u20131252.","DOI":"10.2165\/00002018-200427150-00007"},{"key":"2019111702203906000_R3","doi-asserted-by":"crossref","unstructured":"Andre\u0301s E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15:15\u201321.","DOI":"10.1097\/MOH.0b013e3282f15fb9"},{"key":"2019111702203906000_R4","doi-asserted-by":"crossref","unstructured":"Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004:261\u2013 317.","DOI":"10.1016\/B978-0-443-08559-8.50012-1"},{"key":"2019111702203906000_R5","doi-asserted-by":"crossref","unstructured":"Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005;42:137\u2013144.","DOI":"10.1053\/j.seminhematol.2005.04.004"},{"key":"2019111702203906000_R6","doi-asserted-by":"crossref","unstructured":"Garratty G, Arndt PA. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007;23:105\u2013119.","DOI":"10.21307\/immunohematology-2019-328"},{"key":"2019111702203906000_R7","doi-asserted-by":"crossref","unstructured":"Johnson ST, Fueger JT, Gottschall JL. One center\u2019s experience: the serology and drugs associated with drug-induced immune hemolytic anemia \u2013 a new paradigm. Transfusion. 2007;47:697\u2013702.","DOI":"10.1111\/j.1537-2995.2007.01173.x"},{"key":"2019111702203906000_R8","doi-asserted-by":"crossref","unstructured":"Garratty G, Arndt P, Prince HE, Shulman IA. The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production. Br J Haematol. 1993;84:310\u2013315.","DOI":"10.1111\/j.1365-2141.1993.tb03070.x"},{"key":"2019111702203906000_R9","unstructured":"Miescher PA, Gorstein F. Mechanisms of immunogenic platelet damage. In: Johnson SA, Monto RW, Rebuck JW, et al, eds. Blood Platelets. London: Churchill; 1961:671."},{"key":"2019111702203906000_R10","doi-asserted-by":"crossref","unstructured":"Shulman NR. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Ann Int Med1964;60:506\u201320.","DOI":"10.7326\/0003-4819-60-3-506"},{"key":"2019111702203906000_R11","unstructured":"Worlledge SM. Immune drug-induced hemolytic anemias. Semin Hematol. 1973;10:327\u2013344."},{"key":"2019111702203906000_R12","doi-asserted-by":"crossref","unstructured":"Garratty G, Petz LD. Drug-induced immune hemolytic anemia. Am J Med. 1975;58:398.","DOI":"10.1016\/0002-9343(75)90606-3"},{"key":"2019111702203906000_R13","doi-asserted-by":"crossref","unstructured":"Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol. 1984;61:139\u2013143.","DOI":"10.1111\/j.1365-2141.1985.tb04069.x"},{"key":"2019111702203906000_R14","doi-asserted-by":"crossref","unstructured":"Mueller-Eckhardt C, Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev. 1990;4:69\u201377.","DOI":"10.1016\/S0887-7963(90)70249-0"},{"key":"2019111702203906000_R15","unstructured":"Garratty G. Target antigens for red-cell-bound autoanti-bodies. In: Nance SJ, ed. Clinical and Basic Science Aspects of Immunohematology. Arlington, VA: American Association of Blood Banks: 1991;33\u201372."},{"key":"2019111702203906000_R16","unstructured":"Landsteiner K. The Specificity of Serological Reactions. Springfield, IL: Thomas; 1936."},{"key":"2019111702203906000_R17","doi-asserted-by":"crossref","unstructured":"Kitagawa M, Yagi Y, Pressman D. The heterogeneity of combining sites of antibodies as determined by specific immunoadsorbents. II. Comparison of elution patterns obtained with anti-P-azobenzoate antibodies by different kinds of immunoadsorbent and eluting hapten. J Immunol. 1965;95:455\u2013465.","DOI":"10.4049\/jimmunol.95.3.455"},{"key":"2019111702203906000_R18","doi-asserted-by":"crossref","unstructured":"Shulman NR, Reid DM. Mechanisms of drug-induced immunologically mediated cytopenias. Transfus Med Rev. 1993;VII:215\u2013229.","DOI":"10.1016\/S0887-7963(93)70142-X"},{"key":"2019111702203906000_R19","doi-asserted-by":"crossref","unstructured":"Spath P, Garratty G, Petz L. Studies on the immune response to penicillin and cephalothin in humans. II. Immunohematologic reactions to cephalothin administration. J Immunol. 1971;107:860\u2013689.","DOI":"10.4049\/jimmunol.107.3.860"},{"key":"2019111702203906000_R20","doi-asserted-by":"crossref","unstructured":"Garratty G, Arndt PA. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol. 1998;100:777\u2013783.","DOI":"10.1046\/j.1365-2141.1998.00615.x"},{"key":"2019111702203906000_R21","doi-asserted-by":"crossref","unstructured":"Broadberry RE, Farren TW, Bevin SV, et al. Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient\u2019s red cells. Transfus Med. 2004;14:53\u201357.","DOI":"10.1111\/j.0958-7578.2004.00481.x"},{"key":"2019111702203906000_R22","doi-asserted-by":"crossref","unstructured":"Arndt PA, Leger RM, Garratty G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells (letter). Vox Sang. 2003;85:53.","DOI":"10.1046\/j.1423-0410.2003.00323.x"},{"key":"2019111702203906000_R23","doi-asserted-by":"crossref","unstructured":"Arndt P, Garratty G, Isaak E. Bolger M, Lu Q. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and\/or drug-induced nonimmunologic protein adsorption. Transfusion. 2009;49:711\u2013718.","DOI":"10.1111\/j.1537-2995.2008.02028.x"},{"key":"2019111702203906000_R24","doi-asserted-by":"crossref","unstructured":"Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies. Transfusion. 2008;48:2429\u20132434.","DOI":"10.1111\/j.1537-2995.2008.01852.x"},{"key":"2019111702203906000_R25","doi-asserted-by":"crossref","unstructured":"Garratty G. Immune cytopenia associated with antibiotics. Transfus Med Rev. 1993;VII:255\u2013267.","DOI":"10.1016\/S0887-7963(93)70145-5"},{"key":"2019111702203906000_R26","doi-asserted-by":"crossref","unstructured":"Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and\/or positive direct antiglobulin tests. Transfusion. 1999;39:1239\u20131246.","DOI":"10.1046\/j.1537-2995.1999.39111239.x"},{"key":"2019111702203906000_R27","doi-asserted-by":"crossref","unstructured":"Viraghavan R, Chakravarty AG, Soreth J. Cefotetan-induced haemolytic anaemia. A review of 85 cases. Adv Drug React Toxicol Rev. 2002;21:101\u2013107.","DOI":"10.1007\/BF03256184"},{"key":"2019111702203906000_R28","doi-asserted-by":"crossref","unstructured":"Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol. 1999;181:103\u2013104.","DOI":"10.1016\/S0002-9378(99)70443-6"},{"key":"2019111702203906000_R29","doi-asserted-by":"crossref","unstructured":"Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8:73\u201379.","DOI":"10.1517\/14740330802577351"},{"key":"2019111702203906000_R30","doi-asserted-by":"crossref","unstructured":"Davenport RD, Judd WJ, Dake LR. Persistence of cefotetan on red blood cells. Transfusion. 2004;44:849\u2013852.","DOI":"10.1111\/j.1537-2995.2004.03360.x"},{"key":"2019111702203906000_R31","doi-asserted-by":"crossref","unstructured":"Kapur G, Valentini RP, Mattoo TK, Warrier I, Imam AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer. 2008;50:139\u2013142.","DOI":"10.1002\/pbc.20839"},{"key":"2019111702203906000_R32","doi-asserted-by":"crossref","unstructured":"Quillen K, Lane C, Hu E, Pelton S, Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J. 2008;27:357\u2013358.","DOI":"10.1097\/INF.0b013e3181629a55"},{"key":"2019111702203906000_R33","doi-asserted-by":"crossref","unstructured":"Arndt PA, Garratty G. Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol. 2002;118:256\u2013262.","DOI":"10.1309\/JFJE-VUKN-221T-G6EV"},{"key":"2019111702203906000_R34","doi-asserted-by":"crossref","unstructured":"Anderson AD, Nelson JM, Rossiter S, Angulo FJ. Public health consequences of use of antimicrobial agents in food animals in the United States. Microb Drug Resist. 2003;9:373\u2013379.","DOI":"10.1089\/107662903322762815"},{"key":"2019111702203906000_R35","doi-asserted-by":"crossref","unstructured":"Shea KM. Nontherapeutic use of antimicrobial agents in animal agriculture: implications for pediatrics. Pediatrics. 2004;114:862\u2013868.","DOI":"10.1542\/peds.2004-1233"},{"key":"2019111702203906000_R36","doi-asserted-by":"crossref","unstructured":"Longo G. Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia. Eur J Haematol. 1997;59:124\u2013125.","DOI":"10.1111\/j.1600-0609.1997.tb00737.x"},{"key":"2019111702203906000_R37","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol. 1986;39:713\u2013716.","DOI":"10.1136\/jcp.39.7.713"},{"key":"2019111702203906000_R38","unstructured":"Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80\u201397."},{"key":"2019111702203906000_R39","unstructured":"Johnson S, Smith AG, Lo\u0308ffler H, et al. Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432\u20131438."},{"key":"2019111702203906000_R40","doi-asserted-by":"crossref","unstructured":"Borthakur G, O\u2019Brien S, Wierda W, et al. Immune leukemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol. 2007;136:800\u2013805.","DOI":"10.1111\/j.1365-2141.2007.06513.x"},{"key":"2019111702203906000_R41","doi-asserted-by":"crossref","unstructured":"Umlas J, Turner LA. Antibodies to hydrocortisone in reagent red cells causing positive antibody screening tests. Transfusion. 1993;33:686\u2013688.","DOI":"10.1046\/j.1537-2995.1993.33893342753.x"},{"key":"2019111702203906000_R42","doi-asserted-by":"crossref","unstructured":"Martinengo M, Ardenghi DF, Triopdi G, Reali G. The first case of drug-induced immune hemolytic anemia due to hydrocortisone. Transfusion. 2008;48:1925\u20131929.","DOI":"10.1111\/j.1537-2995.2008.01797.x"},{"key":"2019111702203906000_R43","doi-asserted-by":"crossref","unstructured":"Salama A, Mueller-Eckhardt C, Kissel K. Ex vivo antigen preparation for the serological detection of drug-dependent antibodies in immune haemolytic anaemias. Br J Haematol. 1984;58:525\u2013531","DOI":"10.1111\/j.1365-2141.1984.tb04000.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/73\/645360\/073_079ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/73\/645360\/073_079ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T21:37:00Z","timestamp":1685223420000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/73\/19772\/Druginduced-immune-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.73","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}